A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain

  1. Lihong Zhan
  2. Li Fan
  3. Lay Kodama
  4. Peter Dongmin Sohn
  5. Man Ying Wong
  6. Gergey Alzaem Mousa
  7. Yungui Zhou
  8. Yaqiao Li
  9. Li Gan  Is a corresponding author
  1. Gladstone Institutes, United States
  2. Weill Cornell Medicine, United States

Abstract

Microglia are the resident myeloid cells in the central nervous system (CNS). The majority of microglia rely on CSF1R signaling for survival. However, a small subset of microglia in mouse brains can survive without CSF1R signaling and reestablish the microglial homeostatic population after CSF1R signaling returns. Using single-cell transcriptomic analysis, we characterized the heterogeneous microglial populations under CSF1R inhibition, including microglia with reduced homeostatic markers and elevated markers of inflammatory chemokines and proliferation. Importantly, MAC2/Lgals3 was upregulated under CSF1R inhibition, and shared striking similarities with microglial progenitors in the yolk sac and immature microglia in early embryos. Lineage-tracing studies revealed that these MAC2+ cells were of microglial origin. MAC2+ microglia were also present in non-treated adult mouse brains and exhibited immature transcriptomic signatures indistinguishable from those that survived CSF1R inhibition, supporting the notion that MAC2+ progenitor-like cells are present among adult microglia.

Data availability

The raw count matrix of the scRNA-seq data can be accessed on GEO with accession number (GSE150169). A list of R codes used for the analyses are available on Github (https://github.com/lifan36/Zhan-Fan-et-al-2019-scRNAseq).

The following data sets were generated

Article and author information

Author details

  1. Lihong Zhan

    Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Li Fan

    Helen and Robert Appel Alzheimer's Disease Institute, Weill Cornell Medicine, New York, United States
    Competing interests
    No competing interests declared.
  3. Lay Kodama

    Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, United States
    Competing interests
    No competing interests declared.
  4. Peter Dongmin Sohn

    Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, United States
    Competing interests
    No competing interests declared.
  5. Man Ying Wong

    Helen and Robert Appel Alzheimer's Disease Institute, Weill Cornell Medicine, New York, United States
    Competing interests
    No competing interests declared.
  6. Gergey Alzaem Mousa

    Helen and Robert Appel Alzheimer's Disease Institute, Weill Cornell Medicine, New York, United States
    Competing interests
    No competing interests declared.
  7. Yungui Zhou

    Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, United States
    Competing interests
    No competing interests declared.
  8. Yaqiao Li

    Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Li Gan

    Helen and Robert Appel Alzheimer's Disease Institute, Weill Cornell Medicine, New York, United States
    For correspondence
    lig2033@med.cornell.edu
    Competing interests
    Li Gan, Li Gan is a founder of Aeton Therapeutics, Inc..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4600-275X

Funding

National Institutes of Health (1R01AG054214-01A1)

  • Li Gan

National Institutes of Health (U54NS100717)

  • Li Gan

National Institutes of Health (R01AG051390)

  • Li Gan

Tau Consortium grant

  • Li Gan

National Institute of Aging (F30 AG062043-02)

  • Lay Kodama

National Institutes of Health (T32GM007618)

  • Lay Kodama

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Beth Stevens, Boston Children's Hospital, United States

Ethics

Animal experimentation: All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#AN173162-02) of the University of California, San Francisco.

Version history

  1. Received: September 11, 2019
  2. Accepted: October 14, 2020
  3. Accepted Manuscript published: October 15, 2020 (version 1)
  4. Version of Record published: October 27, 2020 (version 2)

Copyright

© 2020, Zhan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,624
    Page views
  • 530
    Downloads
  • 41
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lihong Zhan
  2. Li Fan
  3. Lay Kodama
  4. Peter Dongmin Sohn
  5. Man Ying Wong
  6. Gergey Alzaem Mousa
  7. Yungui Zhou
  8. Yaqiao Li
  9. Li Gan
(2020)
A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain
eLife 9:e51796.
https://doi.org/10.7554/eLife.51796

Share this article

https://doi.org/10.7554/eLife.51796

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.